

# Yi Qin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2300520/publications.pdf>

Version: 2024-02-01

55  
papers

2,356  
citations

201674

27  
h-index

223800

46  
g-index

55  
all docs

55  
docs citations

55  
times ranked

3706  
citing authors

#	ARTICLE	IF	CITATIONS
1	GOLM1 Modulates EGFR/RTK Cell-Surface Recycling to Drive Hepatocellular Carcinoma Metastasis. <i>Cancer Cell</i> , 2016, 30, 444-458.	16.8	174
2	The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer. <i>Theranostics</i> , 2018, 8, 5072-5087.	10.0	139
3	FBW7-NRA41-SCD1 axis synchronously regulates apoptosis and ferroptosis in pancreatic cancer cells. <i>Redox Biology</i> , 2021, 38, 101807.	9.0	135
4	ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. <i>Cell Research</i> , 2015, 25, 561-573.	12.0	112
5	Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going. <i>Experimental and Molecular Medicine</i> , 2017, 49, e406-e406.	7.7	108
6	ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. <i>Cancer Letters</i> , 2016, 374, 127-135.	7.2	104
7	UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer. <i>Cancer Letters</i> , 2019, 452, 226-236.	7.2	99
8	Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer. <i>Gut</i> , 2020, 69, 888-900.	12.1	99
9	Ferroptosis: Final destination for cancer?. <i>Cell Proliferation</i> , 2020, 53, e12761.	5.3	73
10	FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3950-3960.	7.0	72
11	PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis. <i>Cell Communication and Signaling</i> , 2019, 17, 30.	6.5	72
12	LSD1 sustains pancreatic cancer growth via maintaining HIF1 $\alpha$ -dependent glycolytic process. <i>Cancer Letters</i> , 2014, 347, 225-232.	7.2	63
13	Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 1725-1741.	6.1	53
14	<i>Gas1</i> Inhibits Metastatic and Metabolic Phenotypes in Colorectal Carcinoma. <i>Molecular Cancer Research</i> , 2016, 14, 830-840.	3.4	51
15	ARF6, induced by mutant Kras, promotes proliferation and Warburg effect in pancreatic cancer. <i>Cancer Letters</i> , 2017, 388, 303-311.	7.2	46
16	Role of angiogenesis in pancreatic cancer biology and therapy. <i>Biomedicine and Pharmacotherapy</i> , 2018, 108, 1135-1140.	5.6	46
17	PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells. <i>Cancer Research</i> , 2019, 79, 133-145.	0.9	46
18	Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma. <i>Molecular Cancer Research</i> , 2017, 15, 201-212.	3.4	45

#	ARTICLE	IF	CITATIONS
19	TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1 $\alpha$ axis and indicates prognosis in pancreatic cancer. <i>Cell Death and Disease</i> , 2018, 9, 321.	6.3	45
20	CAPG enhances breast cancer metastasis by competing with PRMT5 to modulate STC-1 transcription. <i>Theranostics</i> , 2018, 8, 2549-2564.	10.0	44
21	New insights into perineural invasion of pancreatic cancer: More than pain. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 111-122.	7.4	39
22	Management of solid pseudopapillary neoplasms of pancreas: A single center experience of 243 consecutive patients. <i>Pancreatology</i> , 2019, 19, 681-685.	1.1	38
23	Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. <i>Cancer Letters</i> , 2015, 360, 227-233.	7.2	37
24	Lipid raft involvement in signal transduction in cancer cell survival, cell death and metastasis. <i>Cell Proliferation</i> , 2022, 55, e13167.	5.3	36
25	Pin1 promotes pancreatic cancer progression and metastasis by activation of NF $\kappa$ B feedback loop. <i>Cell Proliferation</i> , 2020, 53, e12816.	5.3	32
26	Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 1001-1012.	5.4	31
27	Epithelial $\rightarrow$ mesenchymal transition in pancreatic cancer: Is it a clinically significant factor?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 43-49.	7.4	29
28	Homeodomain $\rightarrow$ interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/cMyc axis in pancreatic cancer. <i>Cell Proliferation</i> , 2019, 52, e12603.	5.3	29
29	Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy. <i>Frontiers in Endocrinology</i> , 2021, 12, 679000.	3.5	29
30	The Relationship of Redox With Hallmarks of Cancer: The Importance of Homeostasis and Context. <i>Frontiers in Oncology</i> , 2022, 12, 862743.	2.8	28
31	Critical role of oncogenic KRAS in pancreatic cancer (Review). <i>Molecular Medicine Reports</i> , 2016, 13, 4943-4949.	2.4	27
32	Energy sources identify metabolic phenotypes in pancreatic cancer. <i>Acta Biochimica Et Biophysica Sinica</i> , 2016, 48, 969-979.	2.0	24
33	Prognostic and diagnostic significance of galectins in pancreatic cancer: a systematic review and meta-analysis. <i>Cancer Cell International</i> , 2019, 19, 309.	4.1	24
34	FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. <i>Oncology Reports</i> , 2017, 38, 2069-2077.	2.6	23
35	MiR $\rightarrow$ 29a, targeting caveolin 2 expression, is responsible for limitation of pancreatic cancer metastasis in patients with normal level of serum CA125. <i>International Journal of Cancer</i> , 2018, 143, 2919-2931.	5.1	23
36	Laparoscopic pancreaticoduodenectomy: are the best times coming?. <i>World Journal of Surgical Oncology</i> , 2019, 17, 81.	1.9	23

#	ARTICLE	IF	CITATIONS
37	<sc>dCK</sc> negatively regulates the <sc>NRF</sc>2/<sc>ARE</sc> axis and <sc>ROS</sc> production in pancreatic cancer. <i>Cell Proliferation</i> , 2018, 51, e12456.	5.3	22
38	Papillary-like main pancreatic duct invaginated pancreaticojejunostomy versus duct-to-mucosa pancreaticojejunostomy after pancreaticoduodenectomy: A prospective randomized trial. <i>Surgery</i> , 2015, 158, 1211-1218.	1.9	21
39	Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2/ITGB7/FAK axis. <i>Oncogene</i> , 2020, 39, 6572-6588.	5.9	21
40	A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolism. <i>International Journal of Oncology</i> , 2017, 50, 1792-1800.	3.3	20
41	Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Cancer</i> , 2017, 8, 3615-3622.	2.5	20
42	Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma. <i>Cancer Cell International</i> , 2019, 19, 49.	4.1	19
43	Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1866, 177-188.	7.4	18
44	SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer. <i>Cancer Letters</i> , 2021, 499, 265-278.	7.2	16
45	Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells. <i>American Journal of Cancer Research</i> , 2020, 10, 1182-1193.	1.4	16
46	Prognostic Significance of Altered ATRX/DAXX Gene in Pancreatic Neuroendocrine Tumors: A Meta-Analysis. <i>Frontiers in Endocrinology</i> , 2021, 12, 691557.	3.5	15
47	MTAP Deficiency Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting <i>De Novo</i> Purine Synthesis and Glycolysis in Pancreatic Cancer. <i>Cancer Research</i> , 2021, 81, 4964-4980.	0.9	15
48	Zinc finger E-box-binding homeobox 1 mediates aerobic glycolysis via suppression of sirtuin 3 in pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2018, 24, 4893-4905.	3.3	15
49	FGFBP1, a downstream target of the FBW7/c-Myc axis, promotes cell proliferation and migration in pancreatic cancer. <i>American Journal of Cancer Research</i> , 2019, 9, 2650-2664.	1.4	10
50	SETD8 induces stemness and epithelial&ndash;mesenchymal transition of pancreatic cancer cells by regulating ROR1 expression. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021, 53, 1614-1624.	2.0	7
51	Function and regulation of E-box/WD repeat-containing protein 7 (Review). <i>Oncology Letters</i> , 2020, 20, 1526-1534.	1.8	7
52	FGFBP1-mediated crosstalk between fibroblasts and pancreatic cancer cells via FGF22/FGFR2 promotes invasion and metastasis of pancreatic cancer. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021, 53, 997-1008.	2.0	5
53	ALDOA inhibits cell cycle arrest induced by DNA damage via the ATM-PLK1 pathway in pancreatic cancer cells. <i>Cancer Cell International</i> , 2021, 21, 514.	4.1	5
54	Value of lymphadenectomy in patients with surgically resected pancreatic neuroendocrine tumors. <i>BMC Surgery</i> , 2022, 22, 160.	1.3	5

#	ARTICLE	IF	CITATIONS
55	Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nabâ€paclitaxel in pancreatic cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e398.	4.0	1